NEW YORK (360Dx) – InBios announced today that it has received 510(k) clearance from the US Food and Drug Administration for an antibody-based point-of-care, rapid test that detects Chagas disease.

The firm's Chagas Detect Plus Rapid Test Kit, developed in collaboration with the Infectious Disease Research Institute in Seattle, employs an immunochromatographic strip assay to detect human IgG antibodies to Trypanosoma cruzi in human serum and whole blood matrices, including venous and capillary whole blood.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Oct
12
Sponsored by
PierianDx

This webinar will be a roundtable discussion on the adoption of a commercial gene panel for tumor profiling at several leading US cancer centers. 

Oct
17

This webinar will discuss the benefits of genomically profiling the immune microenvironment of soft tissue sarcomas during neoadjuvant therapy.

Oct
19

This webinar will discuss how new quantitative polymerase chain reaction (qPCR) and reverse transcription qPCR (RT-qPCR) tests can accelerate the discovery and development of much-needed anti-malarial drugs and vaccines.